AU2017332367B2 - High mobility group box i mutant - Google Patents

High mobility group box i mutant Download PDF

Info

Publication number
AU2017332367B2
AU2017332367B2 AU2017332367A AU2017332367A AU2017332367B2 AU 2017332367 B2 AU2017332367 B2 AU 2017332367B2 AU 2017332367 A AU2017332367 A AU 2017332367A AU 2017332367 A AU2017332367 A AU 2017332367A AU 2017332367 B2 AU2017332367 B2 AU 2017332367B2
Authority
AU
Australia
Prior art keywords
seq
vaccinia virus
virus
pfu
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017332367A
Other languages
English (en)
Other versions
AU2017332367A1 (en
Inventor
Stephen H. Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017332367A1 publication Critical patent/AU2017332367A1/en
Application granted granted Critical
Publication of AU2017332367B2 publication Critical patent/AU2017332367B2/en
Priority to AU2022200169A priority Critical patent/AU2022200169B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2017332367A 2016-09-21 2017-09-21 High mobility group box i mutant Active AU2017332367B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200169A AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662397523P 2016-09-21 2016-09-21
US62/397,523 2016-09-21
PCT/US2017/052746 WO2018057755A1 (en) 2016-09-21 2017-09-21 High mobility group box i mutant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200169A Division AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Publications (2)

Publication Number Publication Date
AU2017332367A1 AU2017332367A1 (en) 2019-04-11
AU2017332367B2 true AU2017332367B2 (en) 2021-12-23

Family

ID=61691108

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017332367A Active AU2017332367B2 (en) 2016-09-21 2017-09-21 High mobility group box i mutant
AU2022200169A Expired - Fee Related AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200169A Expired - Fee Related AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Country Status (7)

Country Link
US (2) US11065286B2 (enExample)
EP (1) EP3515419A4 (enExample)
JP (1) JP2019528753A (enExample)
KR (1) KR20190059297A (enExample)
CN (1) CN110022867A (enExample)
AU (2) AU2017332367B2 (enExample)
WO (1) WO2018057755A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
CN111936622B (zh) * 2018-01-19 2024-05-28 可隆生命科学株式会社 重组痘苗病毒和包含其的药物组合物
JP2021522784A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス
CN116162654A (zh) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 用于癌症免疫疗法的重组痘病毒
KR102661908B1 (ko) * 2019-08-29 2024-04-29 주식회사 바이오녹스 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물
WO2022109133A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
EP4604982A2 (en) * 2022-10-19 2025-08-27 KaliVir Immunotherapeutics, Inc. Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285860A1 (en) * 2008-04-04 2009-11-19 The General Hospital Corporation Cancer immunotherapy
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
US20160235793A1 (en) * 2013-08-22 2016-08-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-Oncolytic Therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258168B2 (en) 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
JP5686814B2 (ja) 2010-09-17 2015-03-18 独立行政法人科学技術振興機構 Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285860A1 (en) * 2008-04-04 2009-11-19 The General Hospital Corporation Cancer immunotherapy
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
US20160235793A1 (en) * 2013-08-22 2016-08-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-Oncolytic Therapies

Also Published As

Publication number Publication date
WO2018057755A1 (en) 2018-03-29
AU2022200169B2 (en) 2025-05-29
EP3515419A1 (en) 2019-07-31
AU2017332367A1 (en) 2019-04-11
KR20190059297A (ko) 2019-05-30
EP3515419A4 (en) 2020-06-10
JP2019528753A (ja) 2019-10-17
US20210338754A1 (en) 2021-11-04
US11065286B2 (en) 2021-07-20
US20190209629A1 (en) 2019-07-11
CN110022867A (zh) 2019-07-16
AU2022200169A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
AU2022200169B2 (en) High mobility group box i mutant
US12246049B2 (en) Oncolytic viruses targeting STAT3
US12318419B2 (en) Platform oncolytic vector for systemic delivery
US20250249054A1 (en) Methods of Treating Cancer
US20220049228A1 (en) Modified Extracellular Enveloped Virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)